Los puntos clave no están disponibles para este artículo en este momento.
Lifileucel demonstrated durable responses and addresses a major unmet need in patients with metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to anti-PD-1 or PD-L1 therapy subset.
Sarnaik et al. (Wed,) studied this question.